Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity
-
Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than 4 in 10 (41.4%) achieving 25% or more weight loss1.
-
Substantial weight loss was consistent across all menopausal stages, as well as major reductions in waist circumference, a key indicator of metabolic health1.
-
Women taking Wegovy® had an average 42–45% lower risk of migraine starting six months after initiation, and a 25% lower risk of depression, compared with menopausal hormone therapy alone2.